Clinical trials: Conjunctivitis, Allergic
Allergic Conjunctivitis
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
To evaluate the efficacy of Combo (Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution) compared to its individual components and vehicle in a population of subjects with allergic conjunctivitis:
- Trial name
- NCT05579730
- Testing
- Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035%
- Where
- 4 sites in United States
- Volunteers
- 188 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions in Subjects with Acute Allergic Conjunctivitis
- Trial name
- NCT03494504
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Where
- 7 sites in United States
- Volunteers
- 318 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Allergic Conjunctivitis
The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
- Trial name
- NCT04207736
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 95 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Allergic Rhinitis, Conjunctivitis
Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants
Primary objective: To assess the efficacy of a single dose of the anti- Bet v 1 monoclonal antibodies (mAb(s ) in the reduction of allergic nasal symptoms during an out-of-season birch allergen environmental exposure unit (EEU)…
- Trial name
- NCT05430919
- Testing
- REGN5713, REGN5714, REGN5715
- Where
- 3 sites in Canada
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Allergic Conjunctivitis
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered…
- Trial name
- NCT06686472
- Testing
- TL-925
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Telios Pharma, Inc.
Conjunctivitis, Allergic
A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)
This study was a double-blind, placebo-controlled, cross-over, single-center study of desloratadine 5 mg or placebo in subjects 18 years of age or older with a history of seasonal allergic rhinoconjunctivitis.
- Trial name
- NCT00311844
- Testing
- desloratadine
- Volunteers
- 41 people
- Sponsor
- Organon and Co
Allergic Conjunctivitis
A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults
The main goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles* of MDI-1228_mesylate Ophthalmic Solution in healthy adult participants.
- Trial name
- NCT05969236
- Testing
- MDI-1228_mesylate Ophthalmic Solution
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shanghai Medinno Pharmaceutical Technology Co., Ltd.
Allergic Conjunctivitis
A Study Of TL-925 For The Treatment of AC
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 70 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered…
- Trial name
- NCT06293820
- Testing
- TL-925
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Telios Pharma, Inc.
Allergic Rhinitis Due to Cat Allergy
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat
The primary objective of the study is to determine the efficacy of REGN1908-1909, as compared to placebo, to reduce allergic rhinitis/conjunctivitis symptoms and allergy rescue medication use during natural cat exposure.
- Trial name
- NCT04981717
- Testing
- REGN1908-1909
- Where
- 92 sites in United States, Belgium and 4 more
- Volunteers
- 446 people
- Sponsor
- Regeneron Pharmaceuticals
Allergic Conjunctivitis
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.
The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen…
- Trial name
- NCT00769886
- Testing
- Ketotifen/naphazoline, Ketotifen, Naphazoline
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Bausch & Lomb Incorporated
Seasonal Allergic Conjunctivitis
A Study to Evaluate the Efficacy and Safety of Epinastine Hydrochloride Eye Drops in the Treatment of Chinese Seasonal Allergic Conjunctivitis Patients
The goal of this multicenter, randomized, double-blind, active control, non-inferiority clinical trial is to evaluate the efficacy of epinastine hydrochloride eye drops for the treatment of seasonal allergic conjunctivitis using…
- Trial name
- NCT06212973
- Testing
- Epinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph Soln, Azelastine Hcl Oph Sol+Simulating Epinastine Hcl Oph Soln
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Allergic Conjunctivitis, Seasonal Allergies
A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis
This is a randomized, parallel, single center, double masked, vehicle controlled study. The purpose of this study is to determine the activity and safety of NS2 in patients with grass, tree or ragweed-pollen induced seasonal…
- Trial name
- NCT02578914
- Testing
- NS2 Ophthalmic Drops (0.5%), NS2 Ophthalmic Drops Vehicle (0.0%)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Allergic Conjunctivitis
A Study of TL-925 for the Treatment of Allergic Conjunctivitis
In this prospective Phase 2, single-center, randomized, double-masked, placebo-controlled study, approximately 70 subjects with allergic conjunctivitis will be randomized 1:1 to receive either TL-925 or placebo as topical…
- Trial name
- NCT06153342
- Testing
- TL-925
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Telios Pharma, Inc.
Allergic Conjunctivitis
Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
This is a phase 2 study that will consist of 4 visits over a 5 week period. Drug will be evaluated using the conjunctival allergen challenge model of allergic conjunctivitis.
- Trial name
- NCT00836485
- Testing
- Ketotifen 4.0% Patch, Olopatadine 0.2%, Artificial tears
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Senju USA, Inc.
Allergic Conjunctivitis
A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle
A Single-Center study to demonstrate the non-inferiority of EM-100 to Zaditor® in the treatment of ocular itching.
- Trial name
- NCT03489941
- Testing
- EM-100, Zaditor®, Vehicle
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis, Dry Eye
PMCF Study to Evaluate Performance and Safety of "Optrex Double Action Soothing and Lubricating Drops"
Allergic conjunctivitis (or ocular allergy) and dry eye disease (DED) are two major ocular surface disorders affecting millions of people.
- Conditions
- Allergic Conjunctivitis, Dry Eye, Dry Eye Disease
- Trial name
- NCT05824000
- Testing
- Eye drops for itchy and water eyes
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- C.O.C. Farmaceutici S.r.l.
Allergic Conjunctivitis, Dry Eye
PMCF Study to Evaluate Performance and Safety of "Xanoftal Next"
Dry eye disease (DED), also called keratoconjunctivitis sicca, is a multifactorial disease of the ocular surface characterized by loss of homeostasis of the tear film and accompanied by symptoms such as ocular discomfort and…
- Conditions
- Allergic Conjunctivitis, Dry Eye, Dry Eye Disease
- Trial name
- NCT05829499
- Testing
- HPMC-HA eyedrops
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- C.O.C. Farmaceutici S.r.l.
Allergic Conjunctivitis
Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis
The purpose of this study is to evaluate the efficacy of ST266 ophthalmic drops compared to placebo for the treatment of the signs and symptoms of allergic conjunctivitis.
- Trial name
- NCT02978183
- Testing
- ST266, Saline (0.9% NaCl)
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Allergic Conjunctivitis
A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis
- Trial name
- NCT03231969
- Testing
- Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6%
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Faes Farma, S.A.
Allergic Conjunctivitis
A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.
To evaluate the efficacy of Bilastine ophthalmic solution 0.6% compared to vehicle and Zaditen (Ketotifen ophthalmic solution 0.025%) for the treatment of the signs and symptoms of allergic conjunctivitis.
- Trial name
- NCT03479307
- Testing
- Bilastine Ophthalmic Solution 0.6%, Ketotifen Ophthalmic Solution 0.025% (Zaditen), Vehicle of Bilastine Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 228 people
- Sponsor
- Faes Farma, S.A.